Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis (MPS) I

Phase 1

Terminated

• Conditions: Mucopolysaccharidosis I; Lysosomal Storage Diseases; Spinal Cord Compression
• Interventions: Drug: laronidase

• Registration Number: NCT00215527
• Lead Sponsor: Patricia I. Dickson, M.D.

Brief Summary

The investigators are studying the use of enzyme replacement therapy into the spinal fluid for treatment of spinal cord compression in the Hurler-Scheie and Scheie forms of mucopolysaccharidosis I (MPS I). Funding source -- FDA OOPD

Detailed Description

Enzyme replacement therapy (ERT) has been developed for mucopolysaccharidosis I (MPS I), a lysosomal storage disorder. ERT helps many physical ailments due to the disease, but does not treat the central nervous system, due to inability to cross the blood brain barrier. Our purpose is to test delivery of ERT to the spinal fluid via intrathecal injection in patients with MPS I. In this pilot study, we will use recombinant human α-L-iduronidase administered intrathecally once per month for four months to individuals with the Hurler-Scheie and Scheie forms of MPS I and spinal cord compression. If successful, intrathecal delivery could represent a practical, straightforward method of treating central nervous system disease due to lysosomal storage.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2005-09-19
• Study First Submitted QC: 2005-09-19
• Study First Posted: 2005-09-22
• Study Start: 2005-11
• Primary Completion: 2011-10
• Study Completion: 2011-10
• Status Verified: 2013-02
• Last Update Submitted: 2013-02-20
• Last Update Posted: 2013-02-21

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 4

Inclusion Criteria

• Hurler-Scheie,Scheie form of MPS I, of Hurler 2 years after hematopoietic stem cell transplantation
• Spinal cord compression
• Age greater than 8 years
• Able to provide legal informed consent
• Aware of clinical treatment option of observation without treatment or surgical decompression
• Negative urine pregnancy test at screening (non-sterile females of child-bearing potential only)
• Currently using two acceptable methods of birth control (non-sterile females of child-bearing potential who are sexually active only)
• Willing and able to comply with study procedures

Read More

Exclusion Criteria

• Severe (Hurler) form of MPS I
• Desires surgical or medical treatment of spinal cord compression
• Spinal cord compression that warrants immediate surgical intervention
• Pregnancy or lactation
• Hematopoietic stem cell transplantation within 2 years of study enrollment
• Receipt of an investigational drug within 30 days of enrollment
• Infusion reactions to laronidase that required medical intervention, prophylaxis, or altered enzyme administration
• Significant anti-iduronidase antibody titer
• Recent initiation of intravenous laronidase (within past 6 months)
• Presence of cervical subluxation or similar external pathology as the major cause of cord compression symptoms for which surgical intervention should be immediately undertaken

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
intrathecal laronidase	laronidase	laronidase dose 1.74 mg, route intrathecal, frequency every 30 days, duration three months

Primary Outcome Measures

Name	Time	Method
safety of intrathecal enzyme treatment by blood and spinal fluid tests each month	four months

Secondary Outcome Measures

Name	Time	Method
improvement in spinal cord compression due to mucopolysaccharidosis I	four months

Trial Locations

Locations (2)

Los Angeles Biomedical Research Institute at Harbor-UCLA ( LA BioMed ); 🇺🇸 Torrance, California, United States

Helsinki University Central Hospital; 🇫🇮 Helsinki, Finland